Xiamen Kingdomway Group (002626.SZ) subsidiary's Brazilian sweet protein product receives U.S. FDA GRAS No Questions Letter.

Xiamen Kingdomway Group (002626.SZ) announced that recently, its wholly-owned subsidiary Inner Mongolia Xiamen Kingdomway Group Pharmaceutical Co., Ltd. (hereinafter referred to as "Xiamen Kingdomway Group Pharmaceutical") received a GRAS Notice No. GRN 001305 No Questions Letter issued by the U.S. Food and Drug Administration (FDA). Xiamen Kingdomway Group Pharmaceutical's Brazzein preparation product has completed the FDA GRAS notification evaluation, and the FDA issued a no-objection opinion on the GRAS (Generally Recognized as Safe) conclusion for the product under its declared use. Brazzein preparation is a protein-based high-intensity sweetener, approximately 500-2000 times sweeter than sucrose. It can be used as a general-purpose sweetener in the food sector and has good blending compatibility. Brazzein does not participate in the human sugar metabolism pathway, will not raise blood sugar, and is broken down into amino acids after entering the human body, providing almost no calories. It meets the needs of sugar-conscious consumers and weight-loss consumers, and has broad market application prospects. The Brazzein preparation product of Xiamen Kingdomway Group Pharmaceutical obtaining the U.S. FDA GRAS No Questions Letter marks that the safety conclusion of the product has passed the FDA's official review without objection, and the product has an important compliance foundation for entering the U.S. food market. This is conducive to the company's related products expanding into overseas markets, enriching the company's food ingredient product matrix and revenue sources, enhancing the company's comprehensive competitiveness in the synthetic biology field, and is expected to have a positive impact on the company's future development.